186 related articles for article (PubMed ID: 38231412)
41. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
42. Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
Li Q; Lyu C; Liu M; Wang J; Mou N; Jiang E; Zhang R; Deng Q
Cell Transplant; 2023; 32():9636897231158155. PubMed ID: 36879459
[TBL] [Abstract][Full Text] [Related]
43. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice.
Hu X; Manner K; DeJesus R; White K; Gattis C; Ngo P; Bandoro C; Tham E; Chu EY; Young C; Wells F; Basco R; Friera A; Kangeyan D; Beauchesne P; Dowdle WE; Deuse T; Fry TJ; Foster AE; Schrepfer S
Nat Commun; 2023 Apr; 14(1):2020. PubMed ID: 37037829
[TBL] [Abstract][Full Text] [Related]
44. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract][Full Text] [Related]
45. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement.
Suematsu M; Yagyu S; Yoshida H; Osone S; Nakazawa Y; Sugita K; Imamura T; Iehara T
Cancer Immunol Immunother; 2023 Apr; 72(4):957-968. PubMed ID: 36214866
[TBL] [Abstract][Full Text] [Related]
46. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Schubert ML; Dietrich S; Stilgenbauer S; Schmitt A; Pavel P; Kunz A; Bondong A; Wegner M; Stadtherr P; Jung S; Ho AD; Müller-Tidow C; Schmitt M; Dreger P
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1575-1580. PubMed ID: 32422254
[TBL] [Abstract][Full Text] [Related]
47. [Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].
Chen HR; Zhang Y; Chen P; Liu XD; Huang Q; Zhang J; Li HM; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1040-1045. PubMed ID: 31418354
[TBL] [Abstract][Full Text] [Related]
48. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.
Li Z; Meng F; Li J; Wu T
Front Immunol; 2022; 13():931452. PubMed ID: 35903089
[TBL] [Abstract][Full Text] [Related]
49. Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia.
Dupouy S; Marchiq I; Derippe T; Almena-Carrasco M; Jozwik A; Fouliard S; Adimy Y; Geronimi J; Graham C; Jain N; Maus MV; Mohty M; Boissel N; Teshima T; Kato K; Benjamin R; Balandraud S
Cancer Res Commun; 2022 Nov; 2(11):1520-1531. PubMed ID: 36970059
[TBL] [Abstract][Full Text] [Related]
50. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
51. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Gauthier J; Bezerra ED; Hirayama AV; Fiorenza S; Sheih A; Chou CK; Kimble EL; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Jamieson AW; Bar M; Cassaday RD; Chapuis AG; Cowan AJ; Green DJ; Kiem HP; Milano F; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
Blood; 2021 Jan; 137(3):323-335. PubMed ID: 32967009
[TBL] [Abstract][Full Text] [Related]
52. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells.
Herrera L; Santos S; Vesga MA; Anguita J; Martin-Ruiz I; Carrascosa T; Juan M; Eguizabal C
Sci Rep; 2019 Dec; 9(1):18729. PubMed ID: 31822751
[TBL] [Abstract][Full Text] [Related]
53. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis.
Chen S; Zhang Y; Fang C; Zhang N; Wang Y; Chen R; Li Y; Tu S
Crit Rev Oncol Hematol; 2022 Nov; 179():103807. PubMed ID: 36087853
[TBL] [Abstract][Full Text] [Related]
54. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.
Zhang X; Li JJ; Lu PH
Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556
[TBL] [Abstract][Full Text] [Related]
55. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
[TBL] [Abstract][Full Text] [Related]
56. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
57. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.
Qi Y; Liu H; Li X; Shi Y; Mu J; Li J; Wang Y; Deng Q
Ann Med; 2023 Dec; 55(1):2230888. PubMed ID: 37417690
[TBL] [Abstract][Full Text] [Related]
58. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
59. Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia.
Hu Y; Wu Z; Luo Y; Shi J; Yu J; Pu C; Liang Z; Wei G; Cui Q; Sun J; Jiang J; Xie J; Tan Y; Ni W; Tu J; Wang J; Jin A; Zhang H; Cai Z; Xiao L; Huang H
Clin Cancer Res; 2017 Jul; 23(13):3297-3306. PubMed ID: 28039267
[No Abstract] [Full Text] [Related]
60. A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia.
Wang J; Zhang X; Zhou Z; Liu Y; Yu L; Jia L; Yang J; Li J; Yu H; Li W; Liu G; Rui W; Zheng H; Zhao X; Lin X; Lu P
Am J Hematol; 2022 Aug; 97(8):992-1004. PubMed ID: 35491511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]